Research Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Important Role, Isolation and Basic Concept of Resealed Erythrocytes


Affiliations
1 GNIT College of Pharmacy, Plot No.6 C, Knowledge Park 2, Greater Noida, Uttar Pradesh, 201306, India
2 Department of Pharmaceutics, SGT College of Pharmacy, SGT University Budhera, Gurugram, Haryana 122505, India
     

   Subscribe/Renew Journal


Among the most important being biocompatibility of carrier and its degradation products erythrocytes the most investigated and have found to possess greater potential in drug delivery Erythrocytes, also known as red blood cells, and have been extensively studied for their potential carrier capabilities for the delivery of drugs. The biocompatibility, non-pathogenicity, non-immunogenicity and biodegradability make them unique and useful carriers. Carrier erythrocytes are prepared by collecting blood sample from the organism of interest and separating erythrocytes from plasma. The concept of employing erythrocytes as drug or bio active carrier still needs further optimization a large amount of valuable work is needed so us to utilize the potential of erythrocyte in passive and as well as active targeting of drugs. Disease like cancer would surely find it cure. Genetic engineering aspects can be coupled to give a newer dimension to the existing cellular drug concept.

Keywords

Erythrocytes, Carrier, Blood, Plasma.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Singh Devendra, Kumar Manish, Singh Talever, Singh L.R., Singh Dashrath. A Review on Resealed Erythrocytes as a Carrier for Drug Targeting, International Journal of Pharmaceutical and Biological Archives 2011; 2 (5):1357-1373.

  • Patel RP, Patel MJ and Patel A. An overview of resealed erythrocytes drug deliver, R.P. Patel, journal of pharmacy research 2009; 2(6):1008-1012.

  • A. V. Gothoskar. Resealed Erythrocytes: A Review, www. Pharma. Tech. com, pharma. Tech 2004; 142-143.

  • Gopal V. S., Doijad R.C., and Deshpande P. B. Erythrocytes as a carrier for prednisolone- in vitro and in vivoevaluation, Pak J. Pharm. Sci, 2010;(2) 23:194-200.

  • Green R and Widder K.J. Methods in Enzymology Academic Press, San Diego, 1987: 149.

  • G.J. Tortara B. Derrickson. The Cardiovascular System the Blood in Principles of Anatomy and Physiology, New York, NY, 7th ed., 1993:669-672.

  • Guyton AC and Hall JE. Red Blood Cells, Anemia and Polycytemia, in test book of medical physiology, Saunders WB, Philadelphia, PA, 1996: 425-433.

  • Ropars C., Chassaigne M., and Nicoulau C. Advances in the Biosciences, Pergamon Press, Oxford, 1987: 67.

  • Sackmann Erich, Biological Membranes Architecture and Function Handbook of Biological Physics, ed. R. Lipowsky and E. Sackmann Elsevier 1995: 1.

  • Rajendra Jangde. An Overview of Resealed Erythrocyte for Cancer Therapy, Asian J. Res. Pharm. Sci. 2011;1(4):83-92.

  • V. Jaitely et al. Resealed Erythrocytes: Drug Carrier Potentials and Biomedical Applications, Indian Drugs, 1996; 33:589–594.

  • H.O. Alpar and D.A. Lewis. Therapeutic Efficacy of Asparaginase Encapsulated in Intact Erythrocytes, Biochem. Pharmacol. 1985; 34:257–261.

  • D.A. Lewis. Red Blood Cells for Drug Delivery, Pharm. J., 1984; 32: 384–385.

  • R. Baker. Entry of Ferritin into Human Red Cells during Hypotonic Haemolysis, Nature, 1967; 215: 424–425.

  • U. Sprandel. Towards Cellular Drug Targeting and Controlled Release of Drugs by Magnetic Fields, Adv. Biosci. (Series), 1987; 67: 243–250.

  • K. Kinosita and T.Y. Tsong. Survival of Sucrose-Loaded Erythrocytes in the Circulation, Nature, 1978; 272, 258–260.

  • H.G. Eichler et al. In Vivo Clearance of Antibody-Sensitized Human Drug Carrier Erythrocytes, Clin. Pharmacol. Ther, 1986; 40: 300– 303.

  • M.P. Summer. Recent Advances in Drug Delivery, Pharm. J., 1983; 230, 643–645.

  • H. C. Eichler et.al. In Vitro Drug Release from Human Carrier Erythrocyte AS Carrier System, Advance in Bioscience, 1987; 67:11-15.

  • J. R. DeLoach. Methods in Enzymology, Academic Press, New York, 1987; 235.

  • Carmen Gutierrez Millan, Maria Luisa Sayalero Marinero, Aranzazu Zarzuelo Castaneda and Jose M. Lanao. Drug, enzyme and peptide delivery using erythrocytes as carriers, Journal of Controlled Release, 2004; 95(1): 27-49.

  • Mehrdad Hamidi, Adbolhossein Zarrina, Mahshid Foroozesha and Soliman Mohammadi-Samania. Applications of carrier erythrocytes in delivery of biopharmaceuticals, Journal of Controlled Release, 2007; 118(2):145-160.

  • G.M. Ihler. Erythrocyte Carriers, Pharmacol. Ther.1989; 20:151– 169

  • Torotra G.J. and Grabowski S.R. The Cardiovascular System: The Blood, in Principles of Anatomy and Physiology, Harper Collins College Publishers, New York, NY, 7th ed., 1993; 566–590.

  • Shashank shah. Novel Drug Delivery Carrier: Resealed Erythrocytes, International Journal of Pharma and Bio Sciences, 2011; 2(1): 394‐406.

  • D. A. Tyrrell, B.E. Ryman. Encapsulation of PEG Urease/PEG-AlaDH within Sheep Erythrocytes and Determination of the System’s Activity in Lowering Blood Levels of Urea in Animal Models, biochemistry soc.trans, 1976; 4:677.

  • J.R. DeLoach, G. M. Ihler, Carrier Erythrocyte, Biochem. Biophys. Acta. 1979. 496-136.

  • R. Goldman, T. Facchinetti, D. Bach, A. Raz, M. Shintizky. Activation of Phospholipase A2 by Adriamycin in vitro. Role of Drug-Lipid Interactions, Biochem. Biophys. Acta,1979. 512.

  • M. Hamidi and H.tajerzadeh. Carrier Erythrocyte an Overview, Drug Delivery, 2003; 10:9-20.

  • R. L. Lopez-Marques, L. R. Poulsen, S. Hanisch, K. Meffert, M. J. Buch-Pedersen, M. K. Jakobsen, T. G. Pomorski, and M. G. Palmgren. Intracellular Targeting Signals and Lipid Specificity Determinants of the ALA/ALIS P4-ATPase Complex Reside in the Catalytic ALA {alpha}- Subunit. Mol. Biol. Cell 2010: 21, 791-801

  • X. Zhou and T. R. Graham. Reconstitution of phospholipid translocase activity with purified Drs2p, a type-IV P-type ATPase from budding yeast Proc. Natl. Acad. Sci. USA 2009; 106: 16586-16591

  • J.R. Deloach, R.L. Harris, and G.M. Ihler. An Erythrocyte Encapsu- lator Dialyzer

  • Used in Preparing Large Quantities of Erythrocyte Ghosts and Encapsulation of a Pesticide in Erythrocyte Ghosts, Anal. Biochem.1980; 102, 220–227.

  • J.R. Deloach and G.M. Ihler, A Dialysis Procedure for Loading of Erythrocytes with Enzymes and Lipids, Biochim. Biophys. Acta. 1977; 496, 136–145.

  • U. Benatti et al. Comparative Tissue Distribution and Metabolism of Free Versus Erythrocyte Encapsulated Adriamycin in the Mouse, Adv. Biosci. (Series) 1987. 67, 129– 136.

  • Rechsteiner M.C. Uptake of Protein by Red Cells, Exp. Cell Res. 1975; 43: 487–492.

  • Field W.N., Gamble M.D., and Lewis D.A. A Comparison of Treatment of Thyroidectomized Rats with Free Thyroxin and Thyroxin Encapsulated in Erythrocytes, Int.J. Pharm.1989;51,175–178.

  • Bird J., Best R., and Lewis D.A. The Encapsulation of Insulin in Erythrocytes, J. Pharm. Pharmacol.1983; 35, 246–247.

  • A. Zanella et al. Desferrioxamine Loading of Red Cells for Transfusion, Adv. Biosci. (Series) 1987; 67, 17–27.

  • G. Fiorelli et al. Transfusion of Thalasemic Patients with Desferrioxamine Loaded Standard Red Blood Cell Units, Adv. Biosci. (Series) 1987; 67, 47–54.

  • M.C. Villareal et al. Approach to Optimization of Inositol Hexaphosphate Entrapment into Human Red Blood Cells, Adv. Biosci. (Series) 1987; 67, 55–62.

  • C. Hurel et al. Optimization of Desferrioxamine Loading in Red Blood Cells, Adv. Biosci. (Series) 1987; 67, 37–46.

  • M.C. Villareal et al. Modification of Cardiac Parameters in Piglets after Infusion of IHPLoaded Red Blood Cells, Adv. Biosci. (Series) 1987; 67: 81–88.

  • Gopal VS, Kumar AR, Usha NA, Karthik A, Udupa N. Effective drug targeting by erythrocytes as carrier systems. Curr. Trends Biotechnology. Pharm. 2007. 1,18‐33.

  • Zimmermann U., Riemann F., and Pilwat G. Enzyme Loading of Electrically Homogenous Human Red Blood Cell Ghosts Prepared by Dielectric Breakdown, Biochim. Biophys. Acta.1976; 436, 460– 474.

  • Tson g T.Y. and Kinosita K. Use of Voltage Pulses for the Pore Opening and Drug Loading, and the Subsequent Resealing of Red Blood Cells, Bibl Haematol.1985; 51: 108 – 114.

  • Zimmermann U., Pilwat G., and Riemann F. Preparation of Erythrocyte Ghosts by Dielectric Breakdown of the Cell Membrane, Biochim Biophys Acta.1975; 375 (2):209–219.

  • Jagadale VL, Aloorkar NH, Dohe GH, Gehlot MV. Resealed erythrocytes: an effective tool in drug targeting, Indian J. Pharm. Educ. Res. 2009; 43(4):375‐383.

  • Schrier SL. Shape Changes and Deformability in Human Erythrocyte Membrane, J. Lab. Clin. Med. 1987; 110 (6): 791-797.

  • Kinosita K and Tsong TY. Hemolysis of Human Erythrocytes by a Transient Electric Field, Proc, Natl, Acad. sci. USA, 1977; 74: 1923-1927.

  • Deloach JR, “Encapsulation of Exogenous Agents in Erythrocytes and the Circulating Survival of Carrier Erythrocytes,” J, Appl. Biochem. 1983; 5(3): 149-157.

  • B. Deuticke, M. Kim, and C. Zolinev. The Influence of Amphotericin-B on the Permeability of Mammalian Erythrocytes to Nonelectrolytes, anions and Cations, Biochim. Biophys. Acta. 1973; 318: 345–359.

  • T. Kitao, K. Hattori, and M. Takeshita. Agglutination of Leukemic Cells and Daunomycin Entrapped Erythrocytes with Lectin in Vitro and In Vivo, Experimentia 1978; 341: 94–95.

  • W. Lin et al. Nuclear Magnetic Resonance and Oxygen Affinity Study of Cesium Binding in Human Erythrocytes, Arch Biochem Biophys.1999; 369, (1): 78–88.


Abstract Views: 229

PDF Views: 0




  • Important Role, Isolation and Basic Concept of Resealed Erythrocytes

Abstract Views: 229  |  PDF Views: 0

Authors

Anil Kumar Sahdev
GNIT College of Pharmacy, Plot No.6 C, Knowledge Park 2, Greater Noida, Uttar Pradesh, 201306, India
Bhawana Sethi
Department of Pharmaceutics, SGT College of Pharmacy, SGT University Budhera, Gurugram, Haryana 122505, India

Abstract


Among the most important being biocompatibility of carrier and its degradation products erythrocytes the most investigated and have found to possess greater potential in drug delivery Erythrocytes, also known as red blood cells, and have been extensively studied for their potential carrier capabilities for the delivery of drugs. The biocompatibility, non-pathogenicity, non-immunogenicity and biodegradability make them unique and useful carriers. Carrier erythrocytes are prepared by collecting blood sample from the organism of interest and separating erythrocytes from plasma. The concept of employing erythrocytes as drug or bio active carrier still needs further optimization a large amount of valuable work is needed so us to utilize the potential of erythrocyte in passive and as well as active targeting of drugs. Disease like cancer would surely find it cure. Genetic engineering aspects can be coupled to give a newer dimension to the existing cellular drug concept.

Keywords


Erythrocytes, Carrier, Blood, Plasma.

References